Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has participated in an important research project to develop a magnetic resonance (MR) imaging technique [1,2] that could potentially revolutionize the use of MR imaging in cardiology.

Reducing the procedure time for full evaluation of heart anatomy and function from about one hour down to a few minutes, this new technique has the potential to increase patient access to precision diagnosis, improve patient comfort due to shorter scan times, and lower the cost of care.

CSAM Health Group AS ("CSAM"), the leading provider of niche eHealth solutions in the Nordics, today announced it has signed a deal to acquire eHealth player Optima Corporation Ltd from Chicago, USA-based R1 RCM.

With the acquisition of Optima Corporation, CSAM Health Group will bring market-leading Optima products, impressive customer base and skilled teams in Auckland, New Zealand, Chicago, US, and Reading, UK, into the CSAM family.

Novartis and Hewlett Packard Enterprise (HPE)announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines.

The UK Department of Health and Social Care announced that Qure.ai has been selected as one of the winners of the Artificial Intelligence in Health and Care Award, sponsored by the UK government. Qure.ai is a 5-year-old Sequoia-funded company builds Artificial Intelligence (AI) powered solutions to facilitate identification and treatment of stroke and head injuries.

Orion Health has been listed on the latest NHS London Procurement Partnership framework developed to give NHS organisations access to modern digital technology.

The company has been listed on the Clinical Digital Solutions Framework for three solutions critical to the development of integrated care and population health management.

Royal Philips (NYSE: PHG, AEX: PHIA), and Elekta (EKTA-B.ST) signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions.

The extended collaboration builds on the two companies’ successful cooperation in the fast-emerging field of magnetic resonance (MR)-guided adaptive radiation therapy.

The U.S. Food and Drug Administration authorized marketing of a device to help diagnose autism spectrum disorder (ASD). The Cognoa ASD Diagnosis Aid is a machine learning-based software intended to help health care providers diagnose ASD in children 18 months through 5 years of age who exhibit potential symptoms of the disorder.